PETER TONTONOZ, MD
Medical Practice at Le Conte Ave, Los Angeles, CA

License number
California A65732
Category
Medical Practice
Type
Anatomic Pathology
Address
Address
10833 Le Conte Ave, Los Angeles, CA 90095
Phone
(310) 794-8285
(310) 794-7953
National Provider ID: 1003845785
LicenseFiles verified this license of Nov 7, 2017 at the National Plan and Provider Enumeration System.

Professional information

Peter Tontonoz Photo 1

Professor At Ucla
Position:
Professor at UCLA
Location:
Greater Los Angeles Area
Industry:
Research
Work:
UCLA - Professor

Peter Tontonoz Photo 2

Dr. Peter Tontonoz, Los Angeles CA - MD (Doctor of Medicine)
Specialties:
Anatomic & Clinical Pathology
Address:
Department Ophthalmology
10833 Le Conte Ave STE B-186, Los Angeles 90095
(310) 794-8285 (Phone)
10833 Le Conte Ave STE B-186, Los Angeles 90095
(310) 794-8285 (Phone), (310) 794-8285 (Fax)
UCLA MEDICAL CTR
10833 Le Conte Ave STE A3, Los Angeles 90095
(310) 825-9377 (Phone), (310) 206-5178 (Fax)
Languages:
English
Education:
Medical School
Harvard Medical School
Graduated: 1994
University Ca San Diego Med Center

Peter John Tontonoz Photo 3

Peter John Tontonoz, Los Angeles CA
Specialties:
Pathology, Anatomic Pathology, Anatomic Pathology & Clinical Pathology
Work:
UCLA Medical Center
 10833 Le Conte Ave, Los Angeles, CA 90095
Education:
Harvard University(1996)

Peter Tontonoz Photo 4

Use Of Rar Antagonists As Modulators Of Hormone Mediated Processes

US Patent:
6436993, Aug 20, 2002
Filed:
Jul 13, 1999
Appl. No.:
09/352816
Inventors:
Ronald M. Evans - La Jolla CA
Peter J. Tontonoz - Los Angeles CA
Laszlo Nagy - San Diego CA
Assignee:
The Salk Institute for Biological Studies - La Jolla CA
International Classification:
A61K 3120
US Classification:
514549, 514356, 514443, 514448, 514559, 514475, 514560
Abstract:
In accordance with the present invention, it has been discovered that retinoic acid receptor (RAR) antagonists are capable of modulating processes mediated by other members of the steroid/thyroid hormone receptor superfamily, including permissive receptors such as PPARs (e. g. , PPAR, PPAR and PPAR). Indeed, it has been discovered that RAR antagonists, in combination with agonists for members of the steroid/thyroid hormone receptor superfamily, are capable of inducing and/or enhancing processes mediated by such members.

Peter Tontonoz Photo 5

Treatment Of Disease States Which Result From Neoplastic Cell Proliferation Using Ppar- Activators And Compositions Useful Therefor

US Patent:
6646008, Nov 11, 2003
Filed:
Feb 22, 2000
Appl. No.:
09/331535
Inventors:
Ronald M. Evans - La Jolla CA
Peter Tontonoz - Los Angeles CA
Laszlo Nagy - Debrecen, HU
Assignee:
The Salk Institute for Biological Studies - La Jolla CA
International Classification:
A61K 3119
US Classification:
514573, 514342, 514356, 514690
Abstract:
In accordance with the present invention, it has been discovered that PPAR is expressed consistently in tissues associated with each of a variety of disease states which result from neoplastic cell proliferation. It has further been discovered that maximal activation of PPAR with exogenous ligand promotes terminal differentiation of primary cells which are otherwise subject to neoplastic cell proliferation. In accordance with another aspect of the invention, it has been discovered that RXR-specific ligands are also potent agents for induction of differentiation of cells expressing the PPAR/RXR heterodimer, and that simultaneous treatment of cells subject to neoplastic cell proliferation with a PPAR-selective ligand, in combination with an RXR-specific ligand, results in an additive stimulation of differentiation. Thus, the effect of neoplastic cell proliferation can be ameliorated by treatment of cells undergoing neoplastic cell proliferation with PPAR agonists, optionally in the further presence of RXR agonists, thereby blocking further proliferation thereof. Accordingly, compounds and compositions which are useful for the treatment of a variety of disease states which result from neoplastic cell proliferation have been identified and are described herein.

Peter Tontonoz Photo 6

Treatment Of Liposarcomas Using A Combination Of Thiazolidinediones And Retinoid X Receptor Selective Agonists

US Patent:
6586455, Jul 1, 2003
Filed:
Feb 1, 2000
Appl. No.:
09/331534
Inventors:
Ronald M. Evans - La Jolla CA
Peter Tontonoz - Los Angeles CA
Bruce M. Spiegelman - Waban MA
Barry M. Forman - Newport Beach CA
Assignee:
The Salk Institute for Biological Studies - La Jolla CA
International Classification:
A61K 314406
US Classification:
514369, 514356, 514569, 424464
Abstract:
In accordance with the present invention, it has been discovered that PPAR is expressed consistently in each of the major histologic types of human liposarcoma. It has further been discovered that maximal activation of PPAR with exogenous ligand (a thiazolidinedione or derivative thereof) promotes terminal differentiation of primary human liposarcoma cells. It has still further been discovered that RXR-specific ligands are also potent adipogenic agents in cells expressing the PPAR/RXR heterodimer, and that simultaneous treatment of liposarcoma cells with a thiazolidinedionyl moiety (a PPAR-selective class of compounds) and an RXR-specific ligand results in an additive stimulation of differentiation. Accordingly, according to the invention, there have been identified compositions which are useful for the treatment of liposarcomas.

Medical Practice licenses in California










Other Doctors licenses in California